Recursion Pharmaceuticals Inc Cl A (RXRX)

$5.49 -0.03 (-0.54%)
Market Cap 2.40B
Revenue (ttm) 58.84M
Net Income (ttm) -463.66M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -788.00%
Debt to Equity Ratio 0.02
Volume 49,126,297
Avg Vol 24,039,180
Day's Range N/A - N/A
Shares Out 434.15M
Stochastic %K 81%
Beta 0.91
Analysts Sell
Price Target $6.47

Company Profile

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4...

Industry: Biotechnology
Sector: Healthcare
Phone: 385 269 0203
Fax: 801 821 2872
Address:
41 South Rio Grande Street, Salt Lake City, United States
Bulltrader988
Bulltrader988 Oct. 4 at 7:33 PM
$RXRX nice thread. 👃👀 https://x.com/Sholi_software/status/1974453356870672683?t=z5MXRhfB0A_28YEQuIU7UQ&s=19
0 · Reply
StarksMomentum
StarksMomentum Oct. 4 at 5:31 PM
Been noticing @CarlosRivera_ catching momentum early. If you trade, you’ll want him on your feed💯 $RXRX $RIG $RIVN $AAPL watchlist.
0 · Reply
estatebuyersmia
estatebuyersmia Oct. 4 at 4:45 PM
$RLYB This is an incredible story that no one has understood. $RLYB owns 3.4 mil shares $RXRX, broken down it translates to. 52 cents a share plus they have 45 mil in cash. All said and done the stock trades at 1/3 of its break up value even before its drug program. Factor in the success of RLYB16 and wow......
1 · Reply
davis8uni
davis8uni Oct. 4 at 2:45 PM
$PSNY $RXRX $FRMI $ARBE $ZENA
0 · Reply
MakingMoney20
MakingMoney20 Oct. 4 at 1:50 PM
$RXRX A whole lotta money's going to be made here. For those that get in... RXRX $$
0 · Reply
Spartangio
Spartangio Oct. 4 at 1:46 PM
$RXRX The thread you want to Read https://x.com/sholi_software/status/1974453356870672683?s=46&t=85a54NYUrIhXDU7SWgzM7Q
0 · Reply
Knot2
Knot2 Oct. 4 at 10:05 AM
$RXRX just needs a spark
0 · Reply
The_Owl_
The_Owl_ Oct. 4 at 7:18 AM
$RXRX we must successfully defend the $5.32 - $5.36 support = a move above $5.70 will likely trigger the move toward the primary target of $6.02.
0 · Reply
Spartangio
Spartangio Oct. 4 at 7:06 AM
$RXRX POS piece of six
0 · Reply
Kwasy32
Kwasy32 Oct. 4 at 2:20 AM
$RXRX 43% of the free float shorted … any positive will fly this stock like a rocket …
0 · Reply
Latest News on RXRX
Recursion Pharmaceuticals, Inc. (RXRX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 8, 2025, 8:03 PM EDT - 26 days ago

Recursion Pharmaceuticals, Inc. (RXRX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Recursion Pharmaceuticals, Inc. (RXRX) Presents At Citi's Biopharma Back To School Conference Transcript

Sep 3, 2025, 6:51 PM EDT - 4 weeks ago

Recursion Pharmaceuticals, Inc. (RXRX) Presents At Citi's Biopharma Back To School Conference Transcript

Recursion to Participate in Upcoming Investor Conferences

Aug 27, 2025, 8:00 AM EDT - 5 weeks ago

Recursion to Participate in Upcoming Investor Conferences

Recursion Pharmaceuticals, Inc. (RXRX) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 2:44 PM EDT - 2 months ago

Recursion Pharmaceuticals, Inc. (RXRX) Q2 2025 Earnings Call Transcript

Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 5, 2025, 6:30 AM EDT - 2 months ago

Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update

Recursion to Report Second Quarter 2025 Business Updates and Financial Results on August 5th

Jul 29, 2025, 8:00 AM EDT - 2 months ago

Recursion to Report Second Quarter 2025 Business Updates and Financial Results on August 5th

How Palantir, Tempus, Nvidia-Backed Recursion Are Disrupting Big Pharma

Jul 25, 2025, 1:53 PM EDT - 2 months ago

How Palantir, Tempus, Nvidia-Backed Recursion Are Disrupting Big Pharma

NVDA PLTR

Top 2 Health Care Stocks You May Want To Dump This Quarter

Jul 22, 2025, 7:02 AM EDT - 2 months ago

Top 2 Health Care Stocks You May Want To Dump This Quarter

MEDP

What's Happening With RXRX Stock?

Jul 8, 2025, 7:10 AM EDT - 3 months ago

What's Happening With RXRX Stock?

Recursion to lay off 20% of workforce, narrows focus amid biotech downturn

Jun 10, 2025, 6:14 AM EDT - 4 months ago

Recursion to lay off 20% of workforce, narrows focus amid biotech downturn

MIT and Recursion Release Boltz-2: Next Generation AI Model to Predict Binding Affinity at Unprecedented Speed, Scale, and Accuracy

Jun 6, 2025, 10:00 AM EDT - 4 months ago

MIT and Recursion Release Boltz-2: Next Generation AI Model to Predict Binding Affinity at Unprecedented Speed, Scale, and Accuracy

Recursion Pharmaceuticals, Inc. (RXRX) Q1 2025 Earnings Call Transcript

May 5, 2025, 1:37 PM EDT - 5 months ago

Recursion Pharmaceuticals, Inc. (RXRX) Q1 2025 Earnings Call Transcript

Recursion Reports First Quarter 2025 Financial Results and Provides Business Update

May 5, 2025, 6:00 AM EDT - 5 months ago

Recursion Reports First Quarter 2025 Financial Results and Provides Business Update

Recursion Pharmaceuticals: Looking For Entry Around Q1 Earnings

May 5, 2025, 4:02 AM EDT - 5 months ago

Recursion Pharmaceuticals: Looking For Entry Around Q1 Earnings

Preliminary Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyposis (FAP) Demonstrates Reduced Polyp Burden

May 4, 2025, 12:45 PM EDT - 5 months ago

Preliminary Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyposis (FAP) Demonstrates Reduced Polyp Burden

Recursion to Report First Quarter 2025 Business Updates and Financial Results on May 5th

Apr 28, 2025, 8:27 AM EDT - 5 months ago

Recursion to Report First Quarter 2025 Business Updates and Financial Results on May 5th

Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025

Apr 22, 2025, 8:34 PM EDT - 5 months ago

Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025

HealthVerity Partners with Recursion to Enhance Clinical Trial Analytics with Real-World Data

Apr 16, 2025, 8:30 AM EDT - 6 months ago

HealthVerity Partners with Recursion to Enhance Clinical Trial Analytics with Real-World Data

Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries

Apr 9, 2025, 8:00 AM EDT - 6 months ago

Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries

Recursion to Participate in Upcoming Investor Conference

Apr 1, 2025, 8:00 AM EDT - 6 months ago

Recursion to Participate in Upcoming Investor Conference

Recursion Pharmaceuticals' Update Could Shed Light On Pipeline, Cost-Saving Plans, Analyst Says

Mar 3, 2025, 11:19 AM EST - 7 months ago

Recursion Pharmaceuticals' Update Could Shed Light On Pipeline, Cost-Saving Plans, Analyst Says

Recursion Pharmaceuticals, Inc. (RXRX) Q4 2024 Earnings Call Transcript

Feb 28, 2025, 1:16 PM EST - 7 months ago

Recursion Pharmaceuticals, Inc. (RXRX) Q4 2024 Earnings Call Transcript

Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Feb 28, 2025, 6:30 AM EST - 7 months ago

Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Recursion to Report Fourth Quarter and Fiscal Year 2024 Business Updates and Financial Results on February 28th

Feb 24, 2025, 8:00 AM EST - 7 months ago

Recursion to Report Fourth Quarter and Fiscal Year 2024 Business Updates and Financial Results on February 28th

Altitude Lab Startups Raise $154M in Capital

Feb 18, 2025, 11:00 AM EST - 8 months ago

Altitude Lab Startups Raise $154M in Capital

Recursion: CDK7 Inhibitor Differentiation Is Initially Paying Off

Feb 13, 2025, 6:05 PM EST - 8 months ago

Recursion: CDK7 Inhibitor Differentiation Is Initially Paying Off

Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke Conference

Feb 5, 2025, 5:24 PM EST - 8 months ago

Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke Conference

Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More

Jan 7, 2025, 9:15 AM EST - 9 months ago

Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More

Recursion to Present at 43rd Annual JP Morgan Healthcare Conference

Jan 6, 2025, 8:30 AM EST - 9 months ago

Recursion to Present at 43rd Annual JP Morgan Healthcare Conference

Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules

Dec 20, 2024, 4:05 PM EST - 10 months ago

Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules

Recursion: Transforming Drug Discovery With Its AI-Powered Drug Development Platform

Dec 12, 2024, 6:07 AM EST - 10 months ago

Recursion: Transforming Drug Discovery With Its AI-Powered Drug Development Platform

Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability

Dec 9, 2024, 6:00 PM EST - 10 months ago

Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability

Recursion: Undruggable CDK12 Protein Target Might Be Possible With REC-1245

Dec 9, 2024, 3:14 PM EST - 10 months ago

Recursion: Undruggable CDK12 Protein Target Might Be Possible With REC-1245

Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery

Nov 20, 2024, 7:00 AM EST - 11 months ago

Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery

Recursion and Exscientia Shareholders Approve the Proposed Combination

Nov 13, 2024, 9:08 AM EST - 11 months ago

Recursion and Exscientia Shareholders Approve the Proposed Combination

Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud's Model Garden

Nov 12, 2024, 4:54 PM EST - 11 months ago

Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud's Model Garden

Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6th

Oct 30, 2024, 8:22 AM EDT - 1 year ago

Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6th

Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection

Oct 22, 2024, 8:00 AM EDT - 1 year ago

Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection

Buying Opportunities In Biotech And Pharma With Bhavneesh Sharma

Oct 6, 2024, 2:00 PM EDT - 1 year ago

Buying Opportunities In Biotech And Pharma With Bhavneesh Sharma

AMGN BIIB BLUE BMY CRSP EDIT EXAS

Recursion gets FDA approval to begin phase 1 trials of AI-discovered cancer treatment

Oct 2, 2024, 8:32 AM EDT - 1 year ago

Recursion gets FDA approval to begin phase 1 trials of AI-discovered cancer treatment

Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma

Oct 2, 2024, 8:00 AM EDT - 1 year ago

Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma

Recursion: Path Forward For REC-994 Remains Despite Mixed Response

Sep 4, 2024, 1:03 PM EDT - 1 year ago

Recursion: Path Forward For REC-994 Remains Despite Mixed Response

Recursion's blood vessel disorder drug meets main goal in mid-stage study

Sep 3, 2024, 8:11 AM EDT - 1 year ago

Recursion's blood vessel disorder drug meets main goal in mid-stage study

Recursion CEO on $688M Exscientia acquisition: Hope to bring better medicines to patients sooner

Aug 9, 2024, 9:00 AM EDT - 1 year ago

Recursion CEO on $688M Exscientia acquisition: Hope to bring better medicines to patients sooner

EXAI

Recursion Pharmaceuticals, Inc. (RXRX) Q2 2024 Earnings Call Transcript

Aug 9, 2024, 8:25 AM EDT - 1 year ago

Recursion Pharmaceuticals, Inc. (RXRX) Q2 2024 Earnings Call Transcript

AI-Powered Drug Discovery Firm Exscientia To Merge With Nvidia-Partner Recursion Pharmaceuticals

Aug 8, 2024, 5:37 PM EDT - 1 year ago

AI-Powered Drug Discovery Firm Exscientia To Merge With Nvidia-Partner Recursion Pharmaceuticals

EXAI

CORRECTION - Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results

Aug 8, 2024, 2:41 PM EDT - 1 year ago

CORRECTION - Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results

Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities

Aug 8, 2024, 7:39 AM EDT - 1 year ago

Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities

Biotech firm Recursion to buy smaller peer Exscientia for $688 million

Aug 8, 2024, 7:08 AM EDT - 1 year ago

Biotech firm Recursion to buy smaller peer Exscientia for $688 million

EXAI

Bulltrader988
Bulltrader988 Oct. 4 at 7:33 PM
$RXRX nice thread. 👃👀 https://x.com/Sholi_software/status/1974453356870672683?t=z5MXRhfB0A_28YEQuIU7UQ&s=19
0 · Reply
StarksMomentum
StarksMomentum Oct. 4 at 5:31 PM
Been noticing @CarlosRivera_ catching momentum early. If you trade, you’ll want him on your feed💯 $RXRX $RIG $RIVN $AAPL watchlist.
0 · Reply
estatebuyersmia
estatebuyersmia Oct. 4 at 4:45 PM
$RLYB This is an incredible story that no one has understood. $RLYB owns 3.4 mil shares $RXRX, broken down it translates to. 52 cents a share plus they have 45 mil in cash. All said and done the stock trades at 1/3 of its break up value even before its drug program. Factor in the success of RLYB16 and wow......
1 · Reply
davis8uni
davis8uni Oct. 4 at 2:45 PM
$PSNY $RXRX $FRMI $ARBE $ZENA
0 · Reply
MakingMoney20
MakingMoney20 Oct. 4 at 1:50 PM
$RXRX A whole lotta money's going to be made here. For those that get in... RXRX $$
0 · Reply
Spartangio
Spartangio Oct. 4 at 1:46 PM
$RXRX The thread you want to Read https://x.com/sholi_software/status/1974453356870672683?s=46&t=85a54NYUrIhXDU7SWgzM7Q
0 · Reply
Knot2
Knot2 Oct. 4 at 10:05 AM
$RXRX just needs a spark
0 · Reply
The_Owl_
The_Owl_ Oct. 4 at 7:18 AM
$RXRX we must successfully defend the $5.32 - $5.36 support = a move above $5.70 will likely trigger the move toward the primary target of $6.02.
0 · Reply
Spartangio
Spartangio Oct. 4 at 7:06 AM
$RXRX POS piece of six
0 · Reply
Kwasy32
Kwasy32 Oct. 4 at 2:20 AM
$RXRX 43% of the free float shorted … any positive will fly this stock like a rocket …
0 · Reply
davis8uni
davis8uni Oct. 4 at 1:15 AM
$PSNY $RXRX $FRMI $ARBE $ZENA
0 · Reply
WallStreetWomper
WallStreetWomper Oct. 4 at 1:07 AM
$RXRX
0 · Reply
Spartangio
Spartangio Oct. 3 at 9:47 PM
$RXRX January tic toc 🕰️
0 · Reply
Knot2
Knot2 Oct. 3 at 8:36 PM
$RXRX not even remotely excessively valued
0 · Reply
Bellmarvin
Bellmarvin Oct. 3 at 8:33 PM
. I’m not a trader and I have no charts and I have no level two but from experience, I know the manipulation of the crooked market makers.$RXRX I told you this will close at 5.49
2 · Reply
BiotechAndAI94
BiotechAndAI94 Oct. 3 at 8:23 PM
$GLXY in this and $RXRX
0 · Reply
firefox2778
firefox2778 Oct. 3 at 8:09 PM
$RXRX volume insane today and again a ton of call activity. I don't know, but, if this goes to $100 i'll buy a LAMBO :D https://marketchameleon.com/Overview/RXRX/
1 · Reply
MakingMoney20
MakingMoney20 Oct. 3 at 8:02 PM
$RXRX Back to the Program Monday Morning! RXRX $$
0 · Reply
MakingMoney20
MakingMoney20 Oct. 3 at 7:51 PM
$RXRX We know it's Friday, Lets see if this can end the week right. Get your shares at a bargain! Buy Them Now. RXRX $$
0 · Reply
Vikingsstrade
Vikingsstrade Oct. 3 at 7:50 PM
$GRAB $RXRX $RIG $RIVN Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve.
0 · Reply
Bellmarvin
Bellmarvin Oct. 3 at 7:40 PM
$RXRX this shit will close 5.49 to call the 5,50 calls
0 · Reply
LoveRetailFroth
LoveRetailFroth Oct. 3 at 7:28 PM
$RXRX Look @ the new found resilience & with big volume here ! Shorties need to start covering before weekend 😂🤑🍺
0 · Reply